Hemophilia presents with its own set of challenges when it comes to management. Extended half-life (EHL) recombinant factor VIII drugs promise excellent prophylaxis by reducing dose frequency, enhancing compliance, and improving quality of life while maintaining safety and efficacy. Join us live as Takeda presents a detailed overview of the rationale for Hemophilia management, role of EHL coagulation factors and their use in the treatment of haemophilia. 

Hemophilia Management: Role of EHLs in Prophylaxis

In this session, the focus is on creating awareness and covering unmet medical needs about Prophylaxis and Inhibitor management among the hematologist community, which plays an eminent role in the care of Hemophilia A patients. This insightful session would empower doctors scientifically with the latest clinical acumen and would help in better decision making, thereby building the reputation of Hemophilia doctors.

Hemophilia A Management : Present Challenges and Future Opportunities

Professor, Baba Farid University of Health Sciences, Faridkot Punjab

Dr. Varun Kaul

2

402

7.4k

4.5

Sessions Taken

277

4.7

300

4.3